- Key Takeaways
- Spravato billing requires matching the correct HCPCS code to payer type and dose administered, with J0013, G2082, and G2083 each serving distinct billing pathways.
- J0013 is the permanent HCPCS drug code replacing S0013 effective January 1, 2026, billed in 1 mg increments for Medicaid and commercial non-Medicare payers.
- Medicare reimbursement for G2083, the 84 mg bundled Spravato session code, averages approximately $1,356.08 nationally in 2026, with commercial rates averaging around $1,240.
- G2082 and G2083 apply only to established patients; CMS rules prohibit billing either code for new patient visits, which require a separate E/M code instead.
- CMS bundles drug cost, physician supervision, and the mandatory two-hour observation into a single G-code payment, making separate E/M or prolonged service codes non-billable on the same date.
An estimated 2.8 million U.S. adults with major depressive disorder meet the criteria for treatment-resistant depression, representing nearly 31% of all medicated MDD patients, according to peer-reviewed analyses published through the National Library of Medicine. For the practices now offering Spravato (esketamine) as an FDA-approved treatment for this population, the clinical value is clear. What is far less straightforward is the billing.
Spravato sits at an unusual intersection of drug reimbursement and professional services, governed by a mandatory REMS program, dose-tiered procedure codes, and, beginning January 1, 2026, a significant HCPCS code change that many practices are still catching up with. Submitting the wrong code, pairing it with the wrong modifier, or documenting inconsistently is enough to trigger a denial on a session that can run anywhere from $900 to over $1,600.
If you are new to how Spravato billing works as an operational system, including procurement models, REMS workflows, and in-house vs. outsource decisions, our Spravato billing and coding guide covers that foundation. This article goes one level deeper: a code-by-code breakdown of what changed in 2026, how to select the right code for each session, what documentation supports each, and where claims most often break down.
The 2026 Code Change: Why S0013 Was Replaced by J0013
Effective January 1, 2026, CMS discontinued S0013 and replaced it with J0013 as the HCPCS drug code for esketamine nasal spray. This matters because S-codes are temporary, payer-specific codes that sit outside the permanent HCPCS Level II classification structure. The transition to a J-code reflects esketamine’s move into the permanent drug code taxonomy, signaling its established place in covered outpatient drug reimbursement.
What changed in practice: J0013 is reported in 1 mg increments, meaning the number of units on the claim should equal the total milligrams of esketamine administered during the session. For a 56 mg session, you bill 56 units; for an 84 mg session, 84 units.
J0013 is non-payable by Medicare and is intended for use with Medicaid agencies and other non-Medicare commercial payers. For Medicare beneficiaries, the G-code bundle (G2082 or G2083) remains the appropriate pathway, as it packages the drug cost into the procedure payment.
During this transitional period, some payers may continue to accept J3490, the unclassified drug code, while their systems are updated. Verifying payer-specific readiness for J0013 before submitting claims is essential through early 2026.
Understanding G2082 and G2083: The Dose-Based Procedure Codes
While J0013 handles the drug component for commercial and Medicaid payers, G2082 and G2083 are the procedure codes that capture the full episode of care for Medicare beneficiaries. The selection between them depends on a single factor: the total milligrams administered in that session.
G2082 applies to sessions involving up to 56 mg of esketamine and covers the outpatient evaluation and management of an established patient under physician or qualified healthcare professional supervision, including the required two-hour post-administration observation. G2083 applies when the dose administered exceeds 56 mg, which in clinical practice means an 84 mg session, with the same bundled supervision and observation requirements.
Both codes are bundled, meaning the drug cost, clinical supervision, and two-hour observation are all wrapped into a single payment. The national average Medicare reimbursement rate for G2083 in 2026 is approximately $1,356.08. G2082 reimburses at a lower rate, reflecting the reduced drug cost at the 56 mg dose.
A few selection rules that frequently cause errors in mental health billing claims:
If the supervising healthcare provider does not also supply the drug, they cannot report G2082 or G2083. In a buy-and-bill model where the practice purchases the drug, the G-codes are appropriate. If the drug is dispensed through the patient’s pharmacy benefit and the practice only supervises administration, a different coding pathway applies.
G2082 and G2083 apply only to established patients. Using either code for a new patient visit is a coding error under CMS rules. New patient evaluations require a separate E/M code.
Neither G2082 nor G2083 should be billed alongside a separate E/M code on the same date of service. The supervision and clinical management work is already bundled into the G-code payment. Additionally, 99417 and G2212 may not be reported with the Spravato G-codes on the same date of service.
- Neolytix • Medical Billing
Medical Billing
Quick Reference: Spravato Code Selection Table
Code | What It Covers | Payer Type | Units |
J0013 | Esketamine drug, 1 mg | Medicaid, commercial (non-Medicare) | Total mg administered |
G2082 | Drug + supervision + 2-hr observation, up to 56 mg | Medicare (buy-and-bill) | 1 unit per session |
G2083 | Drug + supervision + 2-hr observation, >56 mg (84 mg) | Medicare (buy-and-bill) | 1 unit per session |
J3490 | Unclassified drug (transitional use only) | Some commercial payers during transition | Per payer guidance |
When to Use J3490 During the Transition
J3490 is the HCPCS code for unclassified drugs and should be treated as a bridge code, not a default. Because J3490 is not tied to a specific drug, claims submitted with this code require supplemental documentation, typically a cover letter or attachment identifying the drug name, NDC, dose, and route of administration.
Use J3490 only when a commercial payer’s system has not yet been updated to accept J0013 and the payer has communicated (directly or through an ERA/remittance) that they still require the unclassified code. Build a workflow to periodically check payer readiness and retire J3490 use with each payer as their systems transition.
Modifier and Place of Service Guidance
Place of service (POS) code directly affects reimbursement, and Spravato is administered in two main settings:
POS 11 (Office): The most common setting for outpatient Spravato treatment. Claims billed under POS 11 use the physician office fee schedule rate.
POS 22 (Hospital Outpatient Department): For settings operating as HOPDs, the applicable code shifts. In a hospital outpatient setting, G0463 (hospital outpatient clinic visit for assessment and management) applies rather than the standard G-codes used in a physician office.
On the modifier front: CMS does not include Spravato (J0013) on its list of HCPCS codes pertaining to single-dose containers, which means the JW and JZ drug wastage modifiers do not apply when billing J0013. This is a notable distinction from many other injectable and infused drugs where waste reporting is required.
Documentation That Supports Each Code
Regardless of which code is used, the claim documentation needs to be contemporaneous, specific, and tied to the REMS compliance record. At a minimum, each session record should include:
- The exact dose of esketamine administered (confirms G2082 vs. G2083 selection)
- Start and end time of the two-hour post-administration observation period
- Vital signs and clinical monitoring notes throughout the observation window
- Confirmation of the patient’s established status
- ICD-10-CM diagnosis code — either F32.2 or F33.2 for TRD, or F32.8x/F33.8 for MDD with acute suicidal ideation, aligning with FDA-approved indications
CMS specifies the ICD-10-CM codes that support medical necessity for G2082 and G2083. Codes F32.5 and F33.42, which indicate MDD in full remission, are only appropriate during the maintenance phase and would not be appropriate for induction phase claims.
REMS compliance documentation, including confirmation of healthcare setting certification and patient enrollment in the REMS program, should be maintained on file even when not submitted with the claim. Spravato must be administered only in a certified healthcare setting, and both outpatient and inpatient facilities must be certified in the SPRAVATO REMS program to legally treat patients.
Managing prior authorization documentation proactively, including documentation of two prior failed antidepressant trials, is what separates practices with consistent Spravato reimbursement from those constantly working denials.
Example Claim Scenarios
Scenario 1: Medicare patient, 56 mg session, physician office
- POS: 11
- Code: G2082 x 1 unit
- ICD-10: F32.2 (Severe MDD, single episode, without psychotic features)
- Documentation needed: Dose confirmation (56 mg), start/end of observation, vitals log, established patient status, REMS enrollment on file
Scenario 2: Commercial payer (non-Medicare), 84 mg session
- Code: J0013 x 84 units (1 unit per mg)
- Add E/M separately if warranted (e.g., 99214 or 99215) for the clinical evaluation — for guidance on selecting the right level, see Neolytix’s psychotherapy billing and coding guide, which covers E/M code selection for psychiatric encounters
- Confirm payer has transitioned to J0013; if not, use J3490 with drug identification attachment
Scenario 3: Medicare, provider supervises but does not supply the drug (pharmacy benefit)
- G2082/G2083 cannot be used
- Bill appropriate E/M codes with prolonged service codes (99415/99416) for clinical staff time
- Verify payer contract for applicable observation service coding
Conclusion
Spravato billing in 2026 is not a set-it-and-forget-it workflow. The S0013-to-J0013 transition alone requires practices to verify each commercial payer’s readiness, update claim templates, and retrain billing staff on unit calculation logic. Layer in the G-code bundling rules, POS-specific nuances, and REMS documentation requirements, and it becomes clear why denial rates in this space remain elevated.
Getting these claims right consistently requires more than a reference table. It requires a billing infrastructure built around Spravato’s unique regulatory and coding environment. For practices managing Spravato as part of a broader psychiatric or behavioral health program, the same discipline needs to extend across the full behavioral health billing operation. And when denials do occur, having a structured denial management process in place, rather than working claims reactively, is what determines how much revenue is actually recovered.
Neolytix’s Spravato billing services are designed specifically for this, covering REMS compliance verification, payer-specific code routing, prior authorization management, and denial resolution for esketamine claims. If your practice is administering Spravato and dealing with inconsistent reimbursement, it may be time to move from workarounds to a purpose-built billing workflow.
- Neolytix • Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
Sources
- CMS Billing and Coding: Esketamine (A59249) — https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=59249
- SPRAVATO REMS Program Overview — https://www.spravatorems.com/pdfs/REMSProgramOverview
- SPRAVATO Access, Coding and Reimbursement Digital Guide (Janssen Pharmaceuticals) — https://www.spravatohcp.com/files/SPRAVATO_Access_Coding_and_Reimbursement_Digital_Guide.pdf
- Prevalence and National Burden of Treatment-Resistant Depression and MDD in the United States, Journal of Clinical Psychiatry — https://www.psychiatrist.com/jcp/prevalence-national-burden-treatment-resistant-depression-major-depressive-disorder-in-us/
- PMC: The Individual and Societal Burden of Treatment-Resistant Depression — https://pmc.ncbi.nlm.nih.gov/articles/PMC11008705/
- FDA REMS Letter for Spravato (esketamine) — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/211243Orig1s013ltr.pdf
- Premera Medical Policy 5.01.609: Spravato (esketamine) — https://www.premera.com/medicalpolicies/5.01.609.pdf
Frequently Asked Questions
Can J0013 be billed to Medicare for Spravato?
No. J0013 is non-payable by Medicare. For Medicare beneficiaries where the practice is purchasing and providing the drug, G2082 or G2083 is the appropriate billing pathway depending on the dose administered.
Do I need to report the NDC code when billing J0013?
Yes, for Medicaid and dual-eligible patients. An 11-digit NDC code and units must accompany the claim to identify the specific drug product administered.
What is the difference between the J0013 code change and what was covered under S0013?
S0013 was a temporary S-code used by commercial and Medicaid payers to identify esketamine at 1 mg per unit. J0013 replaces it with a permanent J-code classification, effective January 1, 2026. The unit structure is the same, but S0013 claims for dates of service on or after January 1, 2026 will be rejected. This transition is covered in more detail in our Spravato billing and coding guide.
Can I bill a separate observation code in addition to G2082 or G2083?
No. The two-hour post-administration observation is already bundled into both G-codes. Billing a separate observation or prolonged service code alongside G2082 or G2083 is considered unbundling and is not compliant with CMS guidelines.
What ICD-10 codes are accepted with the Spravato G-codes?
CMS recognizes specific ICD-10-CM codes tied to FDA-approved indications. TRD is typically coded as F32.2 or F33.2. MDD with acute suicidal ideation uses F32.8x or F33.8 variants. Using a remission code during the induction phase is a common documentation error that can result in claim denial.
